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The diagnostic approach to human disease frequently relies on a pathological 2 assessment of a biopsy from an organ involved in disease. This standard approach not 3 only can define a disease, but also can help determine optimal therapy and provide 4 prognostic information. In a few instances, such as protocol biopsies in solid organ 5 transplant settings, repeated histopathology evaluation can also be useful to evaluate 6 response to therapy [1, 2] . With advancements in our understanding of molecular and 7 cellular pathogenesis of several diseases, it has become apparent that the information 8 obtained from a biopsy can be used to further individualize diagnosis and therapy; a 9 process referred to as precision medicine. For instance, the presence of a specific 10 cellular marker may imply a more aggressive disease and/or determine responsiveness 11 settings, an ideal state-of-the-art tissue-interrogation technology should: 1) allow 21 maximum extraction of the information from specimens of all sizes; 2) be amenable to 22 standardization and reproducibility; 3) enable the production of quantitative analysis that 23 M A N U S C R I P T
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There are at least 18 unique approaches to clearing tissue (as reviewed in 11
Richardson and Lichtman) [13] . These approaches have been developed for a variety of 12 purposes including but not limited to clearing specific organs (i.e. brain), to stabilize 13 membranes and lipid dyes or fluorescent proteins, or to be compatible with and extend 14 existing staining protocols (i.e. immunofluorescence and repeated rounds of 15 immunofluorescence). Taking into consideration clinical restrictions as described 16 above, we can focus on protocols with relatively short durations (within days vs. weeks), 17 that support immunostaining. This leaves ten of the eighteen techniques reviewed: 18 iDISCO, BABB, Sucrose, FocusClear, ClearT2, CUBIC, Clarity, PARS, SWITCH and 19 ACT-PRESTO [13] . Papers using BABB, Sucrose, FocusClear, ClearT2, CUBIC and 20 iDISCO all demonstrate immunostaining. iDISCO is unique in that it was specifically 21 developed to support rapid immunostaining and clearing [18] . Pushing the state-of-the-22 art, SWITCH is especially exciting as 20 successive rounds of immunostaining were 23
demonstrated on large volumes [19] . This is ideal for extracting the maximum amount of 1 information from the limited amount of tissue provided by human biopsies. While it is 2 possible that other protocols based upon hydrogel embedding are also compatible with 3 multiple rounds of immunostaining (e.g, Clarity, PARS, and ACT-PRESTO [20] [21] [22] [23] ) 4 adoption of these techniques is complicated by their reliance on specialized equipment 5 and procedures for electrophoretic tissue clearing. 6 7 While it is difficult to recommend a particular protocol, perhaps the best criterion 8 is the degree to which a protocol has been adopted for research studies. A non-9 rigorous survey of the primary literature in PubMed demonstrates that the iDISCO and 10
Clarity approaches are, to date, amongst the most widely applied when considering the 11 number of years since publication. The choice of technique will also depend upon the 12 outcome of systematic validations in which results obtained from mesoscale analysis of 13 cleared tissues are compared with those obtained from conventional pathology 14 approaches. These validations are critical as there is no guarantee that tissue or organ 15 structure will not be altered by clearing, as tissue shrinkage [16] For instance, in our hands f-actin has proven difficult to stain with some aqueous tissue 16 clearing protocols. As fluorescence-labeled phallotoxin binds between actin monomers 17 in f-actin, we hypothesize that f-actin is labile in the protocols we've tried [27] . 18
Immunofluorescence staining allows for a greater variety of specific and targeted 20 labeling. Antibodies may bind to protein conformations or "discontinuous epitopes" or 21 short peptide sequences [28] . Linear peptide antibodies may be less sensitive to tissue 22 preparations that include denaturation of higher order protein structure [29, 30] . The degree to which cellular and molecular markers are present in specimens is 4 going to be affected by both tissue preparation and underlying pathologies. As tissue 5 clearing can impact the availability of markers, staining with new reagents and new 6 tissues will need to be validated experimentally. Tissue preparation and staining is thus 7 a careful balance between the homogenization of the RIs in a specimen while retaining 8 the salient markers. 9
Imaging Platforms 11
One impetus driving research into tissue clarification has been the concomitant 12 flourishing of optical sectioning microscopes that support three-dimensional imaging. An alternative approach to confocal microscopy is to use an optical sectioning 2 microscope that only excites the imaging focal plane. There are two approaches that 3 accomplish this, 1) multiphoton excitation microscopy and 2) the many variations of 4 light-sheet microscopy (LSM). These modalities have advantages in 3D mesoscale 5 imaging but they also have unique complications. Multiphoton fluorescence microscopy 6 depends upon the simultaneous absorption of two photons, which occurs only at the 7 focus of the objective lens(Reviewed in [44] ). Primarily used to image deep into 8 scattering biological tissues, multiphoton microscopy has also been used to image large 9 cleared tissue at depth [14, 18, 45, 46] . Light sheet microscopy, like confocal 10 microscopy, is a technology that was developed decades ago [47] [48] [49] 
(Reviewed in [50]). 11
In its simplest form, LSM is based upon stimulation of fluorescence by a thin sheet of 12 light, which is imaged by a camera placed orthogonal to the light sheet. LSM's major 13 advantages are 1) its adaptability in imaging large specimens and 2) its speed 14 (Reviewed in Power and Huisken, 2017) [51]. Recently, it has seen a resurgence in 15 imaging naturally clear embryos [52, 53] . Over the past two and half decade's light 16 sheet microscopy has also been applied to imaging other large specimens such as 17 cleared tissue and organs [15, 16, 18, 21-23, 43, 48, 54] . confocal microscopy is also not limited to specific research groups with expertise in 9 building and running microscopes, thanks to the abundance of commercial easy to use 10 platforms. For instance, after a few hours of training a non-expert researcher can be 11 imaging on these platforms. Figure 4A) . Unfortunately, the number of tools that are specifically tailored to 9
analyzing mesoscale 3D datasets is limited. In addition, the ability to perform 10 meaningful analysis on large datasets frequently requires the combination of 11 commercial and custom software whose cost and/or sophistication is beyond the reach 12 of many biomedical researchers. Fortunately, there are many active efforts to improve 13 image analysis approaches in 3D, including solutions for visualization, segmentation 14 and analysis[57-62]. As we discuss below, our own efforts have focused on combining 15 efficient exploration and quantitative analysis of mesoscale 3D image datasets into a 16 single platform that will provide wide accessibility of this powerful approach to the 17 research community. TissueGnostics have brought to market confocal based IHCS systems to support 3D 12 imaging. Whether these novel systems will play a role in large-scale or mesoscale 3D 13
imaging is yet to be seen. Lastly, Definiens' TissueStudio, ImageMiner and XD fill a 14 unique role in the image processing software landscape. Their software integrates 15 segmentation tools, with a well-developed machine learning engine, "Cognition Network 16
Technology" and the capacity for customization by the end user. This customization will 17 prove powerful. For instance, being able to extend segmentation algorithms will make 18 meeting the challenges of segmenting different nuclei possible (Figure 2 vs. Figure 5) . solution to analyze large 3D image volumes and mesoscale datasets of tissue [10] . 17 VTEA was designed around an intuitive interface with a bi-directional workflow to 18 facilitate discovery and provide a framework for extensibility and reproducibility. The 19 unique value of VTEA rests on the following features: 1) it requires mastery of a single 20 software system, 2) the components are organized into an intuitive image analysis 21 workflow accessible to researchers without expertise in image analysis, 3) the various 22 components of the image and data analysis workflow are dynamically interlinked in a bi-23
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directional workflow and 4) has been designed and will include extensible image 1 processing, segmentation, visualization and data interrogation components. VTEA is 2 available for download via the FIJI updater as described at, https://imagej.net/VTEA. The ability to interrogate intact tissues by performing quantitative surveys of specific 6 cells, based on a surface marker label, is an immediate application of this technology. 7
This process, referred to as 3D tissue cytometry (3DTC) is the equivalent of performing 8 flow cytometry to intact tissues, except that the spatial context is preserved, and no bias 9 is introduced through tissue digestion and homogenization. showed that the streamlined approach of VTEA can be easily used to characterize 17 various resident immune cell populations in the mouse kidney [10] . Furthermore, we 18
showed that VTEA analysis can be easily implemented on large-scale volumes, to 19 quantitate immune cell distribution in entire thick sections of human kidney core 20 biopsies. This approach is again demonstrated in Figure 5 , where immune cell 21 distribution using VTEA is shown in a nephrectomy thick section, imaged using a large-22 scale confocal microscopy approach. Because of the 3D nature of the datasets analyzed by VTEA, both the proportion of 2 cells and their spatial density can be measured. This approach is implemented using a 3 region-of-interest based analysis, where VTEA determines the density of specific 4 immune cells in relation to specific structures. In an example from a human kidney 5 biopsy (Figure 6 ), VTEA can distinguish a difference in the density of neutrophils around 6 proximal tubules, based on a spatial parameter specific to these tubules. We also used 7 this approach to measure dendritic cell clustering around glomeruli of mouse kidney 8 [10] . Because measurements are normalized to the imaged volume, density-based 9 measurements will extend the usefulness of VTEA by allowing comparisons not only 10 within a specimen, and but also between different conditions or treatments. Through the 11 extensibility feature in VTEA, the implementation of more complex, machine learning-12 based algorithms (such as cell clustering and shape recognition) will further enhance 13 the automation of analysis. Furthermore, these algorithms will yield rich, "Big-data" 14 style outputs for the hundreds of thousands of cells it already can classify. 15
It is also important to emphasize that, because of the advances in intracellular 17 labeling techniques, and the increasing repertoire of antibodies that can detect the 18 activation of specific pathways, it is now possible to perform 3D quantitative analysis to 19 determine specific pathway activation and signaling in a tissue. For example, through 20 the specific detection of phosphorylated form of cJUN, VTEA can determine the 21 activation of c-Jun-N-terminal kinase (JNK) signaling in a specific cell type (Figure 7) . 22
The functional quantitative data extracted from a tissue, complements the cytometry 23 M A N U S C R I P T
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analysis and provides a molecular context to studying tissue from a specific disease. 1
We can envision the power and complexity of the data obtained from a tissue 2 simultaneously probed for various cell and pathway activation markers, which will allow 3 a precise determination of the cell type(s) activated in a disease process. 4 5
Translational implications 6
Although large-scale 3D quantitative imaging of tissue is not yet used in clinical 7 applications, this approach is being implemented in various venues of translational and 8 clinical research. We are using this approach to aid on-going clinical research by our 9 group in the fields of kidney disease, urology and endocrinology. We expect our 10 approaches will be more widely applicable. Essential to the adoption of this approach 
